Biological product filing citing a paper in the European Journal of Heart Failure — Tectonic Therapeutic, 2025-01-13
Tectonic Therapeutics cited a paper published in the European Journal of Heart Failure as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Tectonic TherapeuticTectonic TherapeuticNASDAQ TECX
Filings SEC · Quote Yahoo on 2025-01-13 was 7.01 Reg FD public · 9.01 financial statements · attached documents. The company cited a paper published in European Journal of Heart Failure in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
Voors et al., European Journal of Heart Failure 2024 JANU AR Y 2025 * Teerlink J.R. et al. Eur.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this extent.
The paper's title is End-organ Protective Effect of Serelaxin in Patients Hospitalized for Heart Failure: Results of the Biomarker Substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2) and it was published in European Journal of Heart Failure on 2024-12-12. The authors' affiliations are University Medical Center Groningen · University of Groningen · Surgical Specialties (Canada) · University of Brescia. The summary published at the beginning of the paper is called abstract. What this article has read is only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and original judgment.
This is a sub-study of a large phase 3 trial in which cerelazine, a drug modeled after pregnancy hormones, was administered by injection for two days to patients hospitalized with acute heart failure, measuring biomarkers separately. Blood samples were taken from 1,020 of the total 6,545 participants immediately after hospitalization and a few days later, comparing numerical indicators reflecting the extent of damage to the heart, kidneys, and liver between the cerelazine group and the placebo group. The cerelazine group showed almost no increase in troponin T, an indicator of heart muscle damage. The placebo group showed an increase of over 40%, and the kidney indicators also worsened less in the cerelazine group. However, the abstract notes that the sub-study group did not show a reduction in mortality from cerelazine.
What the abstract does not answer remains in the full text and appendices. This article leaves the blanks as they are. Readers are to determine which sentence in the abstract corresponds to the cited excerpts by comparing the two citations above.
One month later, the stock price was within the top quarter of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. Dates are counted as trading days, counting only the days when the stock market is open. In terms of the calendar, 20 trading days is approximately one month. The excess return on the day of the regulatory filing and for the following month is presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the regulatory filing | −10.9% | The extent of movement before the filing |
| On the filing date | −5.3% | On the filing date or the first trading day afterward |
| Cumulative over +1 to +5 trading days | +0.0% | One week |
| Cumulative over +1 to +20 trading days | +33.4% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +33.4% in this case is within the top quarter, corresponding to the 96% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +18.7% | +33.4% |
Half of the sample falls between the two central marks on the graph. One checks the table to see whether this case lies within or outside the range. The sample collects cases in which U.S.-listed companies cited papers in 8-K filings over the past ten years. The company itself is excluded from the sample. The numbers listed here are past facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed with only item numbers. In 8-K filings without titles, item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The specific event is read in the original text of each link.
- 2025-01-30 8-K Item 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
- 2025-02-03 8-K Items 1.01,3.02,7.01,9.01 — Material contract execution · Unregistered securities sale · Reg FD disclosure · Financial statements·attached documents
- 2025-03-20 8-K Item 2.02, 9.01 — Earnings Announcement · Financial Statements · Attached Documents
What this article does not answer
This article, based only on abstracts, cannot answer what methods the papers used, what they reviewed, or how far they demonstrated. How many times the cited paper was subsequently cited can be verified again through OpenAlexOpenAlex
Data source · Website citation counts. What will be examined next is whether the company's next 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of the company alone, excluding the portion where the market as a whole rises or falls.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days are approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full paper, one cannot know the details and limitations of the method.